2022
Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis
Garcia-Recio S, Hinoue T, Wheeler G, Kelly B, Garrido-Castro A, Pascual T, De Cubas A, Xia Y, Felsheim B, McClure M, Rajkovic A, Karaesmen E, Smith M, Fan C, Ericsson P, Sanders M, Creighton C, Bowen J, Leraas K, Burns R, Coppens S, Wheless A, Rezk S, Garrett A, Parker J, Foy K, Shen H, Park B, Krop I, Anders C, Gastier-Foster J, Rimawi M, Nanda R, Lin N, Isaacs C, Marcom P, Storniolo A, Couch F, Chandran U, Davis M, Silverstein J, Ropelewski A, Liu M, Hilsenbeck S, Norton L, Richardson A, Symmans W, Wolff A, Davidson N, Carey L, Lee A, Balko J, Hoadley K, Laird P, Mardis E, King T, Perou C. Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis. Nature Cancer 2022, 4: 128-147. PMID: 36585450, PMCID: PMC9886551, DOI: 10.1038/s43018-022-00491-x.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerBreast cancerHER2-targeted therapiesImmune cell infiltratesMetastatic breast tumorsLiver metastasesCell infiltrateLow-pass whole-genome sequencingSubtype changesT cellsEstrogen receptorTumor subtypesEndothelial contentBreast tumorsMetastasisCell-cell adhesion genesReduced expressionGlobal DNA methylationDNA methylation mechanismsFocal deletionsMolecular featuresWhole-genome sequencingCancerSubtypesRNA sequencing
2017
TBCRC 036: Window of opportunity clinical trial reveals adaptive kinome reprogramming in single and combination HER2-targeting in breast cancer (BrCa).
Angus S, Stuhlmiller T, Sciaky N, Chen X, Naim R, Tanioka M, Gallagher K, Forero A, Krop I, Thompson A, Murthy R, He X, Perou C, Earp S, Carey L, Johnson G. TBCRC 036: Window of opportunity clinical trial reveals adaptive kinome reprogramming in single and combination HER2-targeting in breast cancer (BrCa). Journal Of Clinical Oncology 2017, 35: 1027-1027. DOI: 10.1200/jco.2017.35.15_suppl.1027.Peer-Reviewed Original ResearchHER2 targetingOpportunity clinical trialAnti-HER2 drugsKinome reprogrammingKinase-targeted therapiesEligible patientsEvaluable ptsTyrosine kinaseImmune compartmentBreast surgeryHER2 inhibitionMultiplexed Inhibitor BeadsClinical trialsBreast cancerImmune responseSpecific receptor tyrosine kinasesBrCa cellsReceptor tyrosine kinasesTumor cellsKinome responsesHER2Distinct expressionKinase SykResistance mechanismsRNA sequencing